Table 3.
Lifetime cost-effectiveness analysis results
| Lifetime probability of: | A1C ≥7.0% cohort |
A1C <7.0% cohort |
||
|---|---|---|---|---|
| Control | CGM | Control | CGM | |
| Blindness | 14.56 | 12.00 | 16.19 | 13.96 |
| Neuropathy | 34.96 | 30.56 | 33.46 | 30.41 |
| Amputation | 10.53 | 9.13 | 12.92 | 11.73 |
| Microalbuminuria | 19.30 | 13.15 | 12.43 | 9.46 |
| End-stage renal failure | 4.41 | 2.37 | 2.4 | 1.44 |
| Myocardial infarction | 11.53 | 11.24 | 11.24 | 11.04 |
| Ischemic heart disease | 10.41 | 10.22 | 10.82 | 10.66 |
| Congestive heart failure | 2.08 | 2.04 | 1.67 | 1.65 |
| Stroke | 1.94 | 1.92 | 1.84 | 1.81 |
| Life expectancy (means) | 26.79 | 26.84 | 36.54 | 36.58 |
| Discounted QALYs (means) | 13.75 | 14.35 | 16.69 | 17.80 |
| Difference in QALYs | 0.60 | 1.11 | ||
| Discounted direct costs (means) | $159,748 | $217,882 | $200,384 | $285,149 |
| Discounted indirect costs (means) | $441,322 | $441,955 | $1,911,155 | $1,913,776 |
| Discounted total costs (means) | $601,070 | $659,837 | $2,111,539 | $2,198,925 |
| Difference in total costs | $58,767 | $87,386 | ||
| ICER [means (95% CI)] | $98,679 (−60,007 [fourth quadrant, dominant] to −86,582 [second quadrant, dominated]) | $78,943 (14,644 [first quadrant] to −290,780 [second quadrant, dominated]) | ||
Experienced quality-of-life benefit was not statistically significant during the 6-month trial for the A1C ≥7.0% cohort. The A1C ≥7.0% cohort is only for those aged ≥25 years. Dominant, intervention improves health at a lower cost compared with control; Dominated, intervention worsens health at increased cost compared with control.